Company profile: Pleo Pharma
1.1 - Company Overview
Company description
- Provider of pharmaceutical therapeutics development focused on PP-01, an oral prescription medication developed to treat Cannabis Use Disorder and Cannabis Withdrawal Syndrome, which has successfully completed Phase 2 clinical trials.
Products and services
- PP-01: Oral prescription medication engineered to treat Cannabis Use Disorder and Cannabis Withdrawal Syndrome, with Phase 2-completed clinical development
- Treatment Development: PleoPharma architects development of a treatment to help meet the growing demand of an unmet and significant medical condition, applying ethics-compliant pharmaceutical practices
- Ethical Standards Oversight: Company-wide governance ensuring employees and consultants adhere to the highest moral and ethical standards during pharmaceutical activities, reinforcing integrity across development efforts
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Pleo Pharma
Akome Biotech
HQ: Canada
Website
- Description: Provider of psychedelic-based pharmaceuticals for rare diseases and mental disorders, targeting treatments for cluster headaches, Alzheimer’s disease, and depression, serving patients suffering from stroke and neurological illnesses.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Akome Biotech company profile →
Nautilus Neurosciences
HQ: United States
Website
- Description: Provider of specialty pharmaceutical products and services for the treatment of neurological disorders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nautilus Neurosciences company profile →
Impel Pharmaceuticals
HQ: United States
Website
- Description: Provider of intranasal drug treatments for central nervous system disorders, offering Trudhesa, a dihydroergotamine mesylate nasal spray for the acute treatment of migraine with or without aura in adults, and its proprietary Precision Olfactory Delivery (POD) technology targeting the vascular-rich upper nasal space for rapid absorption and consistent bioavailability, alongside partnerships to explore applications with small and large molecules.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Impel Pharmaceuticals company profile →
Concentric Medical
HQ: United States
Website
- Description: Provider of minimally invasive medical devices for use in the neurovasculature, focusing on the design, development, and commercialization of these technologies; headquartered in Mountain View, CA.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Concentric Medical company profile →
Alzheon
HQ: United States
Website
- Description: Provider of clinical-stage treatments for neurodegenerative disorders, including ALZ-801/valiltramiprosate, an oral treatment in Phase 3 testing for Alzheimer’s disease designed to inhibit amyloid oligomer formation; a discovery platform for small molecule inhibitors of protein misfolding; and an expanded access policy for investigational drugs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alzheon company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Pleo Pharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Pleo Pharma
2.2 - Growth funds investing in similar companies to Pleo Pharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Pleo Pharma
4.2 - Public trading comparable groups for Pleo Pharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →